Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415202 | 0.86 | — | — | |
| SCHEMBL2200767 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL74396 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL244740 | 0.82 | — | — | |
| SCHEMBL2948892 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| Methyl Alcohol SCHEMBL27845135 | 0.79 | TP53 (0.54) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| Hydrochloric Acid SCHEMBL6271997 | 0.79 | — | — | |
| SCHEMBL8610883 | 0.79 | TP53 (0.54) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL18408 | 0.77 | — | — | |
| SCHEMBL2833747 | 0.77 | SMN1; SMN2 (0.59) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | claimed |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | claimed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | claimed |
| EP-1740587-A4 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS LLC (US) | 2009-07-15 | — | — | EP | claimed |
| EP-1891039-A1 | QUINOLINE DERIVATIVES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2008-02-27 | — | — | EP | claimed |
| US-7217702-B2 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2007-05-15 | — | — | US | claimed |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | claimed |
| EP-1740587-A2 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | Adenosine Therapeutics, LLC (US) | 2007-01-10 | — | — | EP | claimed |
| WO-2006127329-A1 | QUINOLINE DERIVATIVES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | WO | claimed |
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2005-12-22 | — | — | US | claimed |
| WO-2005097140-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2005-10-20 | — | — | WO | claimed |
| EP-0791592-B1 | Azetidines | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | claimed |
| EP-0765865-B1 | 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION | SEIKAGAKU KOGYO CO LTD (JP) | 2001-12-12 | — | — | EP | claimed |
| EP-0775132-B1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LTD (GB) | 2001-03-28 | — | — | EP | claimed |
| US-5968923-A | ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | claimed |
| US-5763438-A | ANTIVIRAL AGENTS | SEIKAGAKU CORPORATION (JP) | 1998-06-09 | — | — | US | claimed |
| US-5741790-A | Azetidines | PFIZER INC. (US) | 1998-04-21 | — | — | US | claimed |
| EP-0791592-A2 | Azetidines | Pfizer Limited (GB) | 1997-08-27 | — | — | EP | claimed |
| EP-0765865-A1 | 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION | SEIKAGAKU CORPORATION (JP) | 1997-04-02 | — | — | EP | claimed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADORA2A, ADORA2B, ADORA3 | TP53 4285/4885SMN1; SMN2 942/4885CHRNB2 39/4885 |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | FYN, ABL2, LCK | TP53 724/4885SMN1; SMN2 2694/4885CHRNB2 957/4885 |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | KCNQ1, KCNQ2, KCNQ5 | TP53 4456/4885SMN1; SMN2 1298/4885CHRNB2 169/4885 |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNQ5 | TP53 4456/4885SMN1; SMN2 1298/4885CHRNB2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.